No Data
No Data
Shandong Buchang Pharmaceuticals (603858.SH): Its subsidiary Lanzhou Buchang signed a Distribution and License Agreement with LANCET for injection BC001.
Shandong Buchang Pharmaceuticals (603858.SH) announced that its subsidiary, Lanzhou Buchang, intends to sign a Distribution and License Agreement with Russian company LANCET. Lanzhou Buchang intends to license LANCET, as the holder of the product registration, packaging, and quality control for injection BC001 (indications for the treatment of cancer, including advanced gastric cancer and gastroesophageal junction adenocarcinoma) in the Eurasian Economic Union (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan) and Uzbekistan (referred to as 'Region') and as the sole distributor within the Region.
Shandong Buchang Pharmaceuticals (603858.SH) plans to distribute a dividend of RMB 1.26 per 10 shares in 2023, with ex-rights and ex-dividend on August 20th.
Shandong Buchang Pharmaceuticals (603858.SH) announced that the company plans to distribute a cash dividend of 1.2 yuan for every 10 shares in 2023.
Shandong Buchang Pharmaceuticals Obtains Registration Certificate for Fungal Infection Drug
Shandong BUCHANG Pharmaceuticals (603858.SH): Injection acetaminophen obtains pharmaceutical registration certificate.
On August 6th, Ge & Longhui reported that Shandong Buchang Pharmaceuticals (603858.SH), a wholly-owned subsidiary of Tonghua Guhong Pharmaceuticals Co., Ltd., recently received the Drug Registration Certificate issued by the National Medical Products Administration for injection-grade acetylcupanafen. Acetylcupranafen for injection is applicable to adult and pediatric patients (three months and above) with suspected fungal infections with neutrophil count reduction and accompanying fever in empirical treatment or treating candidemia and the following candida infections: abdominal abscess, peritonitis, and pleural cavity infection. The efficacy of this product has not been studied for endocarditis, osteomyelitis, and brain infections caused by candida.
Shandong Buchang Pharmaceuticals (603858.SH): Has accumulated repurchased 2.69% of the company's shares.
On August 1st, Gelunhui reported that Shandong Buchang Pharmaceuticals (603858.SH) had cumulatively repurchased 29,729,053 shares through centralized bidding trading method as of July 31, 2024. The repurchased shares accounted for 2.69% of the total share capital of the company, with the highest purchase price of 17.44 yuan/share and the lowest price of 14.16 yuan/share. The total amount paid for repurchased shares is 472,158,447.03 yuan (excluding transaction fees). The proportion of repurchased shares has a tail difference due to rounding.
Shandong Buchang Ding Shun Pharmaceutical Co., Ltd., a subsidiary of Buchang Pharmaceuticals (603858.SH), is planned to be established with a capital of 19 million yuan.
On July 30, Gelunhui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that in order to improve its global strategy, gain a competitive advantage in the segmented management system, and promote business development, it plans to invest in establishing a holding subsidiary. The specific matters are as follows: 1. The company plans to invest 1.9 million yuan to establish a holding subsidiary "Shandong Buchang Ding Shun Pharmaceutical Co., Ltd." 2. In order to promote a win-win situation for the interests of the company and all parties and create the maximum value for the company and shareholders, Zhao Lu, Cai Yunfei, and Guo Yubiao intend to follow the relevant provisions of the "Shandong Buchang Pharmaceutical Co., Ltd. Equity Investment Project Follow-up Investment Management Measures."
No Data